|
1
|
Jemal A, Murray T, Ward E, Samuels A,
Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics,
2005. CA Cancer J Clin. 55:10–30. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tate MC and Aghi MK: Biology of
angiogenesis and invasion in glioma. Neurotherapeutics. 6:447–457.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grauer OM, Wesseling P and Adema GJ:
Immunotherapy of diffuse gliomas: Biological background, current
status and future developments. Brain Pathol. 19:674–693. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim DH, Kim HK, Kim KM, Kim CK, Jeong MH,
Ko CY, Moon KH and Kang JS: Antibacterial activities of macrolactin
A and 7-O-succinyl macrolactin A from Bacillus
polyfermenticus KJS-2 against vancomycin-resistant
enterococciand methicillin-resistant Staphylococcus aureus. Arch
Pharm Res. 34:147–152. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Romero-Tabarez M, Jansen R, Sylla M,
Lünsdorf H, Häussler S, Santosa DA, Timmis KN and Molinari G:
7-O-Malonyl macrolactin A, a new macrolactin antibiotic form
Bacillus subtilis active against methicillin-resistant
Staphylococcus aureus, vancomycin-resistant Enterococci, and
a small-colony variant of Burkholderia cepacia. Antimicrob
Agents Chemother. 50:1701–1709. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park S, Regmi SC, Park SY, Lee EK, Chang
JH, Ku SK, Kim DH and Kim JA: Protective effect of 7-O-succinyl
macrolactin A against intestinal inflammation is mediated through
PI3-kinase/Akt/mTOR and NF-κB signaling pathways. Eur J Pharmacol.
735:184–192. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chung SU, Hwang SW, Ji YH, Kang JS, Kang
KR, Kang UR, Kim DH and Kim JA: Anti-angiogenic composition
containing macrolactin a and a derivative thereof as active
ingredients. Patent WO2012008674 A1. Filed February 23, 2011;
issued January 19. 2012.
|
|
9
|
Kang Y, Regmi SC, Kim MY, Banskota S,
Gautam J, Kim DH and Kim J: Anti-angiogenic activity of macrolactin
A and its succinyl derivative is mediated through inhibition of
class I PI3K activity and its signaling. Arch Pharm Res.
38:249–260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Regmi SC, Park SY, Kim SJ, Banskota S,
Shah S, Kim DH and Kim JA: The anti-tumor activity of succinyl
macrolactin A is mediated through the β-catenin destruction complex
via the suppression of tankyrase and PI3K/Akt. PLoS One.
10:e01417532015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim YH, Lee JK, Kim B, DeWitt JP, Lee JE,
Han JH, Kim SK, Oh CW and Kim CY: Combination therapy of
cilengitide with belotecan against experimental glioblastoma. Int J
Cancer. 133:749–756. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schmidt KF, Ziu M, Schmidt NO, Vaghasia P,
Cargioli TG, Doshi S, Albert MS, Black PM, Carroll RS and Sun Y:
Volume reconstruction techniques improve the correlation between
histological and in vivo tumor volume measurements in mouse models
of human gliomas. J Neurooncol. 68:207–215. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dirks PB: Brain tumor stem cells: The
cancer stem cell hypothesis writ large. Mol Oncol. 4:420–430. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bar EE, Lin A, Mahairaki V, Matsui W and
Eberhart CG: Hypoxia increases the expression of stem-cell markers
and promotes clonogenicity in glioblastoma neurospheres. Am J
Pathol. 177:1491–1502. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bei R, Marzocchella L and Turriziani M:
The use of temozolomide for the treatment of malignant tumors:
Clinical evidence and molecular mechanisms of action. Recent Pat
Anticancer Drug Discov. 5:172–187. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sher DJ, Henson JW, Avutu B, Hochberg FH,
Batchelor TT, Martuza RL, Barker FG II, Loeffler JS and Chakravarti
A: The added value of concurrently administered tomozolomide versus
adjuvant temozolomide alone in newly diagnosed glioblastoma. J
Neurooncol. 88:43–50. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stupp R, Hegi ME, Neyns B, Goldbrunner R,
Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M,
Dietrich PY, et al: Phase I/IIa study of cilengitide and
temozolomide with concomitant radiotherapy followed by cilengitide
and temozolomide maintenance therapy in patients with newly
diagnosed giloblastoma. J Clin Oncol. 28:2712–2718. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chintala SK, Tonn JC and Rao JS: Matrix
metalloproteinases and their biological function in human gliomas.
Int J Dev Neurosci. 17:495–502. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cifarelli CP, Titus B and Yeoh HK:
Cadherin-dependent adhesion of human U373MG glioblastoma cells
promotes neurite outgrowth and increases migratory capacity:
Laboratory investigation. J Neurosurg. 114:663–669. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Konakondla S and Steven A: Toms: Cerebral
connectivity and high-grade gliomas: Evolving concepts of eloquent
brain in surgery for glioma. AIMS Med Sci. 4:52–70. 2017.
View Article : Google Scholar
|
|
22
|
Gilbert MR, Friedman HS, Kuttesch JF,
Prados MD, Olson JJ, Reaman GH and Zaknoen SL: A phase II study of
temozolomide in patients with newly diagnosed supratentorail
malignant glioma before radiation therapy. Neuro Oncol. 4:261–267.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Davis FG and McCarthy BJ: Current
epidemiological trends and surveillance issues in brain tumors.
Expert Rev Anticancer Ther. 1:395–401. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nabors LB, Mikkelsen T, Rosenfeld SS,
Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K,
Wittemer SM, et al: Phase I and correlative biology study of
cilengitide in patients with recurrent malignant glioma. J Clin
Oncol. 25:1651–1657. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Reardon DA, Fink KL, Mikkelsen T,
Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ,
Rich KM, et al: Randomized phase II study of cilengitide, an
integrin-targeting arginine-glycine-aspartic acid peptide, in
recurrent glioblastoma multiforme. J Clin Oncol. 26:5610–5617.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nabors LB, Mikkelsen T, Hegi ME, Ye X,
Batchelor T, Lesser G, Peereboom D, Rosenfeld MR, Olsen J, Brem S,
et al: A safety run-in and randomized phase 2 study of cilengitide
combined with chemoradiation for newly diagnosed glioblastoma
(NABTT 0306). Cancer. 118:5601–5607. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gilbert MR, Kuhn J, Lamborn KR, Lieberman
F, Wen PY, Mehta M, Cloughesy T, Lassman AB, Deangelis LM, Chang S
and Prados M: Cilengitide in patients with recurrent glioblastoma:
The results of NABTC 03–02, a phase II trial with measures of
treatment delivery. J Neurooncol. 106:147–153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stupp R, Hegi ME, Gorlia T, Erridge SC,
Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, et
al: Cilengitide combined with standard treatment for patients with
newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC
EORTC 26071-22072 study): A multicentre, randomised, open-label,
phase 3 trial. Lancet Oncol. 15:1100–1108. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chinot OL, Wick W, Mason W, Henriksson R,
Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea
D, et al: Bevacizumab plus radiotherapy-temozolomide for newly
diagnosed glioblastoma. N Engl J Med. 370:709–722. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gilbert MR, Dignam JJ, Armstrong TS, Wefel
JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S,
Won M, et al: A randomized trial of bevacizumab for newly diagnosed
glioblastoma. N Engl J Med. 370:699–708. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gustafson K, Roman M and Fenical W: The
macrolactins, a novel class of antiviral and cytotoxic macrolides
from a deep-sea marine bacterium. J Am Chem Soc. 111:7519–7524.
1989. View Article : Google Scholar
|
|
32
|
Kim H, Kim W, Ryoo I, Kim C, Suk J, Han K,
Hwang S and Yoo I: Neuronal cell protection activity of macrolactin
A produced by Actinomadura sp. J Microbiol Biotechnol. 7:429–434.
1997.
|
|
33
|
Bae SH, Kwon MJ, Park JB, Kim D, Kim DH,
Kang JS, Kim CG, Oh E and Bae SK: Metabolic Drug-Drug Interaction
Potential of Macrolactin A and 7-O-Succinyl Macrolactin A Assessed
by Evaluating Cytochrome P450 Inhibition and Induction and
UDP-Glucuronosyltransferase inhibition in vitro. Antimicrob Agents
Chemother. 58:5036–5046. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Keffer J, Probert L, Cazlaris H,
Georgopoulos S, Kaslaris E, Kioussis D and Kollias G: Transgenic
mice expressing human tumour necrosis factor: A predictive genetic
model of arthritis. EMBO J. 10:4025–4031. 1991.PubMed/NCBI
|
|
35
|
Conrad C, Miller CR, Ji Y, Gomez-Manzano
C, Bharara S, McMurray JS, Lang FF, Wong F, Sawaya R, Yung WK and
Fueyo J: Delta24-hyCD adenovirus suppresses glioma growth in vivo
by combining oncolysis and chemosensitization. Cancer Gene Ther.
12:284–294. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jiang H, Gomez-Manzano C, Alemany R,
Medrano D, Alonso M, Bekele BN, Lin E, Conrad CC, Yung WK and Fueyo
J: Comparative effect of oncolytic adenoviruses with E1A-55kDa or
E1B-55kDa deletions in malignant gliomas. Neoplasia. 7:48–56. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Samoto K, Ehtesham M, Perng GC, Hashizume
K, Wechsler SL, Nesburn AB, Black KL and Yu JS: A herpes simplex
virus type 1 mutant with gamma 34.5 and LAT deletions effectively
oncolyses human U87 glioblastomas in nude mice. Neurosurgery.
50:599–606. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kirsch M, Strasser J, Allende R, Bello L,
Zhang J and Black PM: Angiostatin suppresses malignant glioma
growth in vivo. Cancer Res. 58:4654–4659. 1998.PubMed/NCBI
|
|
39
|
Lund EL, Bastholm L and Kristjansen PE:
Therapeutic synergy of TNP-470 and ionizing radiation: Effects on
tumor growth, vessel morphology, and angiogenesis in human
glioblastoma multiforme xenografts. Clin Cancer Res. 6:971–978.
2002.
|
|
40
|
Schmidt NO, Ziu M, Carrabba G, Giussani C,
Bello L, Sun Y, Schmidt K, Albert M, Black PM and Carroll RS:
Antiangiogenic therapy by local intracerebral microinfusion
improves treatment efficiency and survival in an orthotopic human
glioblastoma model. Clin Cancer Res. 10:1255–1262. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Candolfi M, Curtin JF, Nichols WS,
Muhammad AG, King GD, Pluhar GE, McNiel EA, Ohlfest JR, Freese AB,
Moore PF, et al: Intracranial glioblastoma models in preclinical
neuro-oncology: Neuropathological characterization and tumor
progression. J Neurooncol. 85:133–148. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bernstein JJ, Goldberg WJ, Laws ER Jr,
Conger D, Morreale V and Wood LR: C6 glioma cell invasion and
migration of rat brain after neural homografting: Ultrastructure.
Neurosurgery. 26:622–628. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chicoine MR and Silbergeld DL: Invading C6
glioma cells maintaining tumorigenicity. J Neurosurg. 83:665–671.
1995. View Article : Google Scholar : PubMed/NCBI
|
